684 results
Search Results
2. Author Correction: Requirements for the differentiation of innate T-bethigh memory-phenotype CD4+ T lymphocytes under steady state.
- Author
-
Kawabe, Takeshi, Yi, Jaeu, Kawajiri, Akihisa, Hilligan, Kerry, Fang, Difeng, Ishii, Naoto, Yamane, Hidehiro, Zhu, Jinfang, Jankovic, Dragana, Kim, Kwang Soon, Trinchieri, Giorgio, and Sher, Alan
- Subjects
T cells ,TECHNICAL specifications - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. Publisher Correction: Metabolic characteristics of CD8+ T cell subsets in young and aged individuals are not predictive of functionality.
- Author
-
Quinn, Kylie M., Hussain, Tabinda, Kraus, Felix, Formosa, Luke E., Lam, Wai K., Dagley, Michael J., Saunders, Eleanor C., Assmus, Lisa M., Wynne-Jones, Erica, Loh, Liyen, van de Sandt, Carolien E., Cooper, Lucy, Good-Jacobson, Kim L., Kedzierska, Katherine, Mackay, Laura K., McConville, Malcolm J., Ramm, Georg, Ryan, Michael T., and La Gruta, Nicole L.
- Subjects
T cells ,OLDER people - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Author Correction: Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.
- Author
-
Lauss, Martin, Donia, Marco, Harbst, Katja, Andersen, Rikke, Mitra, Shamik, Rosengren, Frida, Salim, Maryem, Vallon-Christersson, Johan, Törngren, Therese, Kvist, Anders, Ringnér, Markus, Svane, Inge Marie, and Jönsson, Göran
- Subjects
CELLULAR therapy ,T cells ,MELANOMA - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
5. Author Correction: In vivo clonal expansion and phenotypes of hypocretin-specific CD4+ T cells in narcolepsy patients and controls.
- Author
-
Jiang, Wei, Birtley, James R., Hung, Shu-Chen, Wang, Weiqi, Chiou, Shin-Heng, Macaubas, Claudia, Kornum, Birgitte, Tian, Lu, Huang, Huang, Adler, Lital, Weaver, Grant, Lu, Liying, Ilstad-Minnihan, Alexandra, Somasundaram, Sriram, Ayyangar, Sashi, Davis, Mark M., Stern, Lawrence J., and Mellins, Elizabeth D.
- Subjects
T cells ,NARCOLEPSY ,OREXINS ,PHENOTYPES - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. Publisher Correction: ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression.
- Author
-
Cao, Yu, Trillo-Tinoco, Jimena, Sierra, Rosa A., Anadon, Carmen, Dai, Wenjie, Mohamed, Eslam, Cen, Ling, Costich, Tara L., Magliocco, Anthony, Marchion, Douglas, Klar, Richard, Michel, Sven, Jaschinski, Frank, Reich, Richard R., Mehrotra, Shikhar, Cubillos-Ruiz, Juan R., Munn, David H., Conejo-Garcia, Jose R., and Rodriguez, Paulo C.
- Subjects
ENDOPLASMIC reticulum ,T cells ,TUMORS - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
7. Enhanced CD95 and interleukin 18 signalling accompany T cell receptor Vβ21.3+ activation in multi-inflammatory syndrome in children.
- Author
-
Zhang, Zhenguang, Kean, Iain R. L., Dratva, Lisa M., Clark, John A., Syrimi, Eleni, Khan, Naeem, Daubney, Esther, White, Deborah, O'Neill, Lauran, Chisholm, Catherine, Payne, Caroline, Benkenstein, Sarah, Kupiec, Klaudia, Galassini, Rachel, Wright, Victoria, Winmill, Helen, Robbins, Ceri, Brown, Katherine, Ramnarayan, Padmanabhan, and Scholefield, Barnaby
- Subjects
T cells ,T cell receptors ,MULTISYSTEM inflammatory syndrome in children ,SYNDROMES in children ,INTERLEUKIN receptors ,KILLER cells ,REGULATORY T cells ,KILLER cell receptors - Abstract
Multisystem inflammatory syndrome in children is a post-infectious presentation SARS-CoV-2 associated with expansion of the T cell receptor Vβ21.3+ T-cell subgroup. Here we apply muti-single cell omics to compare the inflammatory process in children with acute respiratory COVID-19 and those presenting with non SARS-CoV-2 infections in children. Here we show that in Multi-Inflammatory Syndrome in Children (MIS-C), the natural killer cell and monocyte population demonstrate heightened CD95 (Fas) and Interleuking 18 receptor expression. Additionally, TCR Vβ21.3+ CD4+ T-cells exhibit skewed differentiation towards T helper 1, 17 and regulatory T cells, with increased expression of the co-stimulation receptors ICOS, CD28 and interleukin 18 receptor. We observe no functional evidence for NLRP3 inflammasome pathway overactivation, though MIS-C monocytes show elevated active caspase 8. This, coupled with raised IL18 mRNA expression in CD16- NK cells on single cell RNA sequencing analysis, suggests interleukin 18 and CD95 signalling may trigger activation of TCR Vβ21.3+ T-cells in MIS-C, driven by increased IL-18 production from activated monocytes and CD16- Natural Killer cells. Multi-Inflammatory Syndrome in Children (MIS-C) is a severe post-infectious presentation related to SARS-CoV-2 infection. Here authors used multi-omics approaches to characterise MIS-C cases and found increased CD95 and IL-18 signalling accompanying the expansion of TCR Vβ 21.3+ T cells. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Invariant γδTCR natural killer-like effector T cells in the naked mole-rat.
- Author
-
Sanchez Sanchez, Guillem, Emmrich, Stephan, Georga, Maria, Papadaki, Ariadni, Kossida, Sofia, Seluanov, Andrei, Gorbunova, Vera, and Vermijlen, David
- Subjects
T cells ,NAKED mole rat ,T cell receptors ,MOLECULAR recognition ,GENE rearrangement ,NUDITY ,GENE expression profiling ,CYTOTOXINS - Abstract
The naked mole-rat (Heterocephalus glaber) is a long-lived rodent species showing resistance to the development of cancer. Although naked mole-rats have been reported to lack natural killer (NK) cells, γδ T cell-based immunity has been suggested in this species, which could represent an important arm of the immune system for antitumor responses. Here, we investigate the biology of these unconventional T cells in peripheral tissues (blood, spleen) and thymus of the naked mole-rat at different ages by TCR repertoire profiling and single-cell gene expression analysis. Using our own TCR annotation in the naked mole-rat genome, we report that the γδ TCR repertoire is dominated by a public invariant Vγ4-2/Vδ1-4 TCR, containing the complementary-determining-region-3 (CDR3)γ CTYWDSNYAKKLF / CDR3δ CALWELRTGGITAQLVF that are likely generated by short-homology-repeat-driven DNA rearrangements. This invariant TCR is specifically found in γδ T cells expressing genes associated with NK cytotoxicity and is generated in both the thoracic and cervical thymus of the naked mole-rat until adult life. Our results indicate that invariant Vγ4-2/Vδ1-4 NK-like effector T cells in the naked mole-rat can contribute to tumor immunosurveillance by γδ TCR-mediated recognition of a common molecular signal. Naked mole-rats are long-lived rodents known to be resistant to the development of cancer, yet their immune system remains poorly explored. Here, the authors identify natural killer-like effector γδ T cells that express a dominant γδ T cell receptor and may serve a role in tumour immunosurveillance. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Tlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis.
- Author
-
Wang, Pai, Yang, Xin, Zhang, Luyao, Sha, Sha, Huang, Juan, Peng, Jian, Gu, Jianlei, Pearson, James Alexander, Hu, Youjia, Zhao, Hongyu, Wong, F. Susan, Wang, Quan, and Wen, Li
- Subjects
WEIGHT gain ,B cells ,LYMPHOCYTE subsets ,T cells ,DYSBIOSIS ,OBESITY ,INSULIN resistance - Abstract
Toll-like receptor 9 (TLR9) recognizes bacterial, viral and self DNA and play an important role in immunity and inflammation. However, the role of TLR9 in obesity is less well-studied. Here, we generate B-cell-specific Tlr9-deficient (Tlr9
fl/fl /Cd19Cre+/- , KO) B6 mice and model obesity using a high-fat diet. Compared with control mice, B-cell-specific-Tlr9-deficient mice exhibited increased fat tissue inflammation, weight gain, and impaired glucose and insulin tolerance. Furthermore, the frequencies of IL-10-producing-B cells and marginal zone B cells were reduced, and those of follicular and germinal center B cells were increased. This was associated with increased frequencies of IFNγ-producing-T cells and increased follicular helper cells. In addition, gut microbiota from the KO mice induced a pro-inflammatory state leading to immunological and metabolic dysregulation when transferred to germ-free mice. Using 16 S rRNA gene sequencing, we identify altered gut microbial communities including reduced Lachnospiraceae, which may play a role in altered metabolism in KO mice. We identify an important network involving Tlr9, Irf4 and Il-10 interconnecting metabolic homeostasis, with the function of B and T cells, and gut microbiota in obesity. Although the function of Toll-like receptor 9 (TLR9) in immunity and inflammation is well-established, its role in obesity is less well-studied. In this study, the authors demonstrate that TLR9 deficiency in B cells is associated with obesity in mice and results in altered frequencies of T and B lymphocyte subsets and gut microbiome dysbiosis. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
10. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters.
- Author
-
Zaeck, Luca M., Tan, Ngoc H., Rietdijk, Wim J. R., Geers, Daryl, Sablerolles, Roos S. G., Bogers, Susanne, van Dijk, Laura L. A., Gommers, Lennert, van Leeuwen, Leanne P. M., Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Dalm, Virgil A. S. H., Lafeber, Melvin, Kootstra, Neeltje A., Huckriede, Anke L. W., Haagmans, Bart L., van Baarle, Debbie, and Koopmans, Marion P. G.
- Subjects
IMMUNE response ,VACCINE effectiveness ,COVID-19 ,BOOSTER vaccines ,SARS-CoV-2 Omicron variant ,T cells - Abstract
Waning antibody responses after COVID-19 vaccination combined with the emergence of the SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, bivalent mRNA-based booster vaccines encoding the ancestral spike protein in combination with that of Omicron BA.1 or BA.5 were introduced. Since then, different BA.2-descendent lineages have become dominant, such as XBB.1.5, JN.1, or EG.5.1. Here, we report post-hoc analyses of data from the SWITCH-ON study, assessing how different COVID-19 priming regimens affect the immunogenicity of bivalent booster vaccinations and breakthrough infections (NCT05471440). BA.1 and BA.5 bivalent vaccines boosted neutralizing antibodies and T-cells up to 3 months after boost; however, cross-neutralization of XBB.1.5 was poor. Interestingly, different combinations of prime-boost regimens induced divergent responses: participants primed with Ad26.COV2.S developed lower binding antibody levels after bivalent boost while neutralization and T-cell responses were similar to mRNA-based primed participants. In contrast, the breadth of neutralization was higher in mRNA-primed and bivalent BA.5 boosted participants. Combined, our data further support the current use of monovalent vaccines based on circulating strains when vaccinating risk groups, as recently recommended by the WHO. We emphasize the importance of the continuous assessment of immune responses targeting circulating variants to guide future COVID-19 vaccination policies. Waning immunity and the emergence of the SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness and required vaccine updates. Here, the authors assess how different priming regimens affect the immunogenicity of BA.1 and BA.5 bivalent boosters. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity.
- Author
-
Brunet-Ratnasingham, Elsa, Morin, Sacha, Randolph, Haley E., Labrecque, Marjorie, Bélair, Justin, Lima-Barbosa, Raphaël, Pagliuzza, Amélie, Marchitto, Lorie, Hultström, Michael, Niessl, Julia, Cloutier, Rose, Sreng Flores, Alina M., Brassard, Nathalie, Benlarbi, Mehdi, Prévost, Jérémie, Ding, Shilei, Anand, Sai Priya, Sannier, Gérémy, Marks, Amanda, and Wågsäter, Dick
- Subjects
COVID-19 ,IMMUNITY ,ANTIBODY formation ,T cells ,ARTIFICIAL respiration ,HOSPITAL patients - Abstract
Plasma RNAemia, delayed antibody responses and inflammation predict COVID-19 outcomes, but the mechanisms underlying these immunovirological patterns are poorly understood. We profile 782 longitudinal plasma samples from 318 hospitalized patients with COVID-19. Integrated analysis using k-means reveals four patient clusters in a discovery cohort: mechanically ventilated critically-ill cases are subdivided into good prognosis and high-fatality clusters (reproduced in a validation cohort), while non-critical survivors segregate into high and low early antibody responders. Only the high-fatality cluster is enriched for transcriptomic signatures associated with COVID-19 severity, and each cluster has distinct RBD-specific antibody elicitation kinetics. Both critical and non-critical clusters with delayed antibody responses exhibit sustained IFN signatures, which negatively correlate with contemporaneous RBD-specific IgG levels and absolute SARS-CoV-2-specific B and CD4
+ T cell frequencies. These data suggest that the "Interferon paradox" previously described in murine LCMV models is operative in COVID-19, with excessive IFN signaling delaying development of adaptive virus-specific immunity. The role of IFN signaling in SARS-CoV-2 infection and outcome is still debated. Here, the authors longitudinally profiled plasma samples from hospitalized patients and show that a persistent inflammatory response is linked to delayed generation of adaptive immunity and increased risk of death when coupled with severe infection. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
12. Structure and genome editing of type I-B CRISPR-Cas.
- Author
-
Lu, Meiling, Yu, Chenlin, Zhang, Yuwen, Ju, Wenjun, Ye, Zhi, Hua, Chenyang, Mao, Jinze, Hu, Chunyi, Yang, Zhenhuang, and Xiao, Yibei
- Subjects
GENOME editing ,NUCLEIC acids ,T cells ,HUMAN genome ,SYNECHOCYSTIS ,CRISPRS ,IMMUNE system - Abstract
Type I CRISPR-Cas systems employ multi-subunit effector Cascade and helicase-nuclease Cas3 to target and degrade foreign nucleic acids, representing the most abundant RNA-guided adaptive immune systems in prokaryotes. Their ability to cause long fragment deletions have led to increasing interests in eukaryotic genome editing. While the Cascade structures of all other six type I systems have been determined, the structure of the most evolutionarily conserved type I-B Cascade is still missing. Here, we present two cryo-EM structures of the Synechocystis sp. PCC 6714 (Syn) type I-B Cascade, revealing the molecular mechanisms that underlie RNA-directed Cascade assembly, target DNA recognition, and local conformational changes of the effector complex upon R-loop formation. Remarkably, a loop of Cas5 directly intercalated into the major groove of the PAM and facilitated PAM recognition. We further characterized the genome editing profiles of this I-B Cascade-Cas3 in human CD3
+ T cells using mRNA-mediated delivery, which led to unidirectional 4.5 kb deletion in TRAC locus and achieved an editing efficiency up to 41.2%. Our study provides the structural basis for understanding target DNA recognition by type I-B Cascade and lays foundation for harnessing this system for long range genome editing in human T cells. Here the authors present two cryo-EM structures of the Synechocystis sp. PCC 6714 (Syn) type I-B Cascade, revealing the molecular mechanisms that underlie RNA-directed Cascade assembly, target DNA recognition and local conformational changes of the effector complex upon R-loop formation. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
13. Premature skewing of T cell receptor clonality and delayed memory expansion in HIV-exposed infants.
- Author
-
Dzanibe, Sonwabile, Wilk, Aaron J., Canny, Susan, Ranganath, Thanmayi, Alinde, Berenice, Rubelt, Florian, Huang, Huang, Davis, Mark M., Holmes, Susan P., Jaspan, Heather B., Blish, Catherine A., and Gray, Clive M.
- Subjects
T cells ,IMMUNOLOGIC memory ,T cell differentiation ,KILLER cells ,INFANTS ,HIV infection transmission - Abstract
While preventing vertical HIV transmission has been very successful, HIV-exposed uninfected infants (iHEU) experience an elevated risk to infections compared to HIV-unexposed and uninfected infants (iHUU). Here we present a longitudinal multimodal analysis of infant immune ontogeny that highlights the impact of HIV/ARV exposure. Using mass cytometry, we show alterations in T cell memory differentiation between iHEU and iHUU being significant from week 15 of life. The altered memory T cell differentiation in iHEU was preceded by lower TCR Vβ clonotypic diversity and linked to TCR clonal depletion within the naïve T cell compartment. Compared to iHUU, iHEU had elevated CD56
lo CD16lo Perforin+ CD38+ CD45RA+ FcεRIγ+ NK cells at 1 month postpartum and whose abundance pre-vaccination were predictive of vaccine-induced pertussis and rotavirus antibody responses post 3 months of life. Collectively, HIV/ARV exposure disrupted the trajectory of innate and adaptive immunity from birth which may underlie relative vulnerability to infections in iHEU. Here, Dzanibe et al show that in utero HIV/ARV exposure sequentially disrupts infant immunologic trajectories, beginning with NK cells that predict vaccine antibody responses and followed by delayed T cell memory maturation linked to skewed TCR clonality. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
14. The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion.
- Author
-
Uslu, Ugur, Sun, Lijun, Castelli, Sofia, Finck, Amanda V., Assenmacher, Charles-Antoine, Young, Regina M., Chen, Zhijian J., and June, Carl H.
- Subjects
CHIMERIC antigen receptors ,T cells ,CELL physiology ,T cell receptors ,SECRETION - Abstract
As a strategy to improve the therapeutic success of chimeric antigen receptor T cells (CART) directed against solid tumors, we here test the combinatorial use of CART and IMSA101, a newly developed stimulator of interferon genes (STING) agonist. In two syngeneic tumor models, improved overall survival is observed when mice are treated with intratumorally administered IMSA101 in addition to intravenous CART infusion. Transcriptomic analyses of CART isolated from tumors show elevated T cell activation, as well as upregulated cytokine pathway signatures, in particular IL-18, in the combination treatment group. Also, higher levels of IL-18 in serum and tumor are detected with IMSA101 treatment. Consistent with this, the use of IL-18 receptor negative CART impair anti-tumor responses in mice receiving combination treatment. In summary, we find that IMSA101 enhances CART function which is facilitated through STING agonist-induced IL-18 secretion. It has been previously suggested that STING agonists can improve response to CAR-T therapy. Here the authors report the characterization of the STING agonist IMSA101, showing that STING-induced IL18 secretion enhances CAR-T activity in preclinical cancer models. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation.
- Author
-
Berjis, Abdulla, Muthumani, Deeksha, Aguilar, Oscar A., Pomp, Oz, Johnson, Omar, Finck, Amanda V., Engel, Nils W., Chen, Linhui, Plachta, Nicolas, Scholler, John, Lanier, Lewis L., June, Carl H., and Sheppard, Neil C.
- Subjects
CRYOPROTECTIVE agents ,GRANZYMES ,KILLER cells ,FROZEN semen ,T cells ,APOPTOSIS ,GENOME editing ,CYTOTOXINS - Abstract
Human natural killer (NK) cell-based therapies are under assessment for treating various cancers, but cryopreservation reduces both the recovery and function of NK cells, thereby limiting their therapeutic feasibility. Using cryopreservation protocols optimized for T cells, here we find that ~75% of NK cells die within 24 h post-thaw, with the remaining cells displaying reduced cytotoxicity. Using CRISPR-Cas9 gene editing and confocal microscopy, we find that cryopreserved NK cells largely die via apoptosis initiated by leakage of granzyme B from cytotoxic vesicles. Pretreatment of NK cells with a combination of Interleukins-15 (IL-15) and IL-18 prior to cryopreservation improves NK cell recovery to ~90-100% and enables equal tumour control in a xenograft model of disseminated Raji cell lymphoma compared to non-cryopreserved NK cells. The mechanism of IL-15 and IL-18-induced protection incorporates two mechanisms: a transient reduction in intracellular granzyme B levels via degranulation, and the induction of antiapoptotic genes. Natural killer (NK) cells are assessed for various therapies, but sub-optimal cryopreservation dampens their clinical feasibility. Here the authors show that pretreating human NK cells with IL-15/IL-18 prior to cryopreservation improves NK cell post-thaw viability and functions, potentially via anti-apoptosis gene induction and granzyme B degranulation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Primary prophylaxis with mTOR inhibitor enhances T cell effector function and prevents heart transplant rejection during talimogene laherparepvec therapy of squamous cell carcinoma.
- Author
-
Joo, Victor, Abdelhamid, Karim, Noto, Alessandra, Latifyan, Sofiya, Martina, Federica, Daoudlarian, Douglas, De Micheli, Rita, Pruijm, Menno, Peters, Solange, Hullin, Roger, Gaide, Olivier, Pantaleo, Giuseppe, and Obeid, Michel
- Subjects
T cells ,HEART transplantation ,SQUAMOUS cell carcinoma ,IMMUNE response ,CELL physiology ,GRAFT rejection - Abstract
The application of mammalian target of rapamycin inhibition (mTORi) as primary prophylactic therapy to optimize T cell effector function while preserving allograft tolerance remains challenging. Here, we present a comprehensive two-step therapeutic approach in a male patient with metastatic cutaneous squamous cell carcinoma and heart transplantation followed with concomitant longitudinal analysis of systemic immunologic changes. In the first step, calcineurin inhibitor/ mycophenolic acid is replaced by the mTORi everolimus to achieve an improved effector T cell status with increased cytotoxic activity (perforin, granzyme), enhanced proliferation (Ki67) and upregulated activation markers (CD38, CD69). In the second step, talimogene laherparepvec (T-VEC) injection further enhances effector function by switching CD4 and CD8 cells from central memory to effector memory profiles, enhancing Th1 responses, and boosting cytotoxic and proliferative activities. In addition, cytokine release (IL-6, IL-18, sCD25, CCL-2, CCL-4) is enhanced and the frequency of circulating regulatory T cells is increased. Notably, no histologic signs of allograft rejection are observed in consecutive end-myocardial biopsies. These findings provide valuable insights into the dynamics of T cell activation and differentiation and suggest that timely initiation of mTORi-based primary prophylaxis may provide a dual benefit of revitalizing T cell function while maintaining allograft tolerance. Cutaneous squamous cell carcinoma is more frequent and more aggressive in the organ transplanted and represent a therapeutic challenge due to the ongoing transplantrelated immune suppression. Here, the authors present a case report of a patient whose T cell responses were successfully strengthened via primary prophylactic therapy with mammalian target of rapamycin inhibition and intra-lesion injection of the oncolytic herpesvirus T-VEC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial.
- Author
-
Shi, Ming, Wang, Jiaojiao, Huang, Hongming, Liu, Dan, Cheng, Hai, Wang, Xu, Chen, Wei, Yan, Zhiling, Sang, Wei, Qi, Kunming, Li, Depeng, Zhu, Feng, Li, Zhenyu, Qiao, Jianlin, Wu, Qingyun, Zeng, Lingyu, Fei, Xiaoming, Gu, Weiying, Miao, Yuqing, and Xu, Kailin
- Subjects
CHIMERIC antigen receptors ,MULTIPLE myeloma ,CD19 antigen ,CYTOKINE release syndrome ,T cells - Abstract
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 CAR T cells targeting BCMA/CD19 and evaluate antimyeloma activity in vitro and in vivo. Preclinical results indicate that BC19 CAR specifically recognize target antigens, and BC19 CAR T cells mediate selective killing of BCMA or CD19-positive cancer cells. BC19 CAR T cells also exhibit potent antigen-specific anti-tumor activity in xenograft mouse models. We conduct an open-label, single-arm, phase I/II study of BC19 CAR T cells in 50 patients with R/R MM (ChiCTR2000033567). The primary endpoint was safety. BC19 CAR T cells are well tolerated with grade 3 or higher cytokine release syndrome in 8% of patients and grade 1 neurotoxic events in 4% of patients, which meet the pre-specified primary endpoint. Secondary endpoints include overall response rate (92%), median progression-free survival (19.7 months), median overall survival (19.7 months) and median duration of response (not reached). Our study demonstrates that bispecific BC19 CAR T cells are feasible, safe and effective in treating patients with R/R MM. CAR-T cell therapies targeting BCMA have shown promising responses in patients with multiple myeloma (MM), however primary resistance and relapse are frequently observed. Here the authors report the results of a phase I//II study of bispecific CAR T-cells targeting BCMA and CD19 in relapsed/refractory MM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Antiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment.
- Author
-
Keller, Michael D., Hanley, Patrick J., Chi, Yueh-Yun, Aguayo-Hiraldo, Paibel, Dvorak, Christopher C., Verneris, Michael R., Kohn, Donald B., Pai, Sung-Yun, Dávila Saldaña, Blachy J., Hanisch, Benjamin, Quigg, Troy C., Adams, Roberta H., Dahlberg, Ann, Chandrakasan, Shanmuganathan, Hasan, Hasibul, Malvar, Jemily, Jensen-Wachspress, Mariah A., Lazarski, Christopher A., Sani, Gelina, and Idso, John M.
- Subjects
HEMATOPOIETIC stem cell transplantation ,T cells ,CHILD patients ,CELLULAR therapy ,DISEASE risk factors ,HEMATOPOIETIC stem cells ,VIRUS inactivation ,T cell receptors - Abstract
Viral infections remain a major risk in immunocompromised pediatric patients, and virus-specific T cell (VST) therapy has been successful for treatment of refractory viral infections in prior studies. We performed a phase II multicenter study (NCT03475212) for the treatment of pediatric patients with inborn errors of immunity and/or post allogeneic hematopoietic stem cell transplant with refractory viral infections using partially-HLA matched VSTs targeting cytomegalovirus, Epstein-Barr virus, or adenovirus. Primary endpoints were feasibility, safety, and clinical responses (>1 log reduction in viremia at 28 days). Secondary endpoints were reconstitution of antiviral immunity and persistence of the infused VSTs. Suitable VST products were identified for 75 of 77 clinical queries. Clinical responses were achieved in 29 of 47 (62%) of patients post-HSCT including 73% of patients evaluable at 1-month post-infusion, meeting the primary efficacy endpoint (>52%). Secondary graft rejection occurred in one child following VST infusion as described in a companion article. Corticosteroids, graft-versus-host disease, transplant-associated thrombotic microangiopathy, and eculizumab treatment correlated with poor response, while uptrending absolute lymphocyte and CD8 T cell counts correlated with good response. This study highlights key clinical factors that impact response to VSTs and demonstrates the feasibility and efficacy of this therapy in pediatric HSCT. Viral infection is a common risk for immune-compromised individuals, particularly pediatric patients receiving hematopoietic stem cell transplants. Here the authors report a phase II trial testing adoptive transfer of third party, virus-specific T cells on the feasibility, safety, clinical responses, as well as homeostasis of antiviral immunity in the recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
19. Developmental self-reactivity determines pathogenic Tc17 differentiation potential of naive CD8+ T cells in murine models of inflammation.
- Author
-
Lee, Gil-Woo, Kim, Young Ju, Lee, Sung-Woo, Kim, Hee-Ok, Kim, Daeun, Kim, Jiyoung, Kim, You-Me, Kang, Keunsoo, Rhee, Joon Haeng, Chung, Ik Joo, Bae, Woo Kyun, Oh, In-Jae, Yang, Deok Hwan, and Cho, Jae-Ho
- Subjects
T cells ,T cell differentiation ,INFLAMMATORY bowel diseases ,CELL populations ,GRAFT versus host disease ,CELL differentiation - Abstract
The differentiation of naive CD8
+ T cells into effector cells is important for establishing immunity. However, the effect of heterogeneous naive CD8+ T cell populations is not fully understood. Here, we demonstrate that steady-state naive CD8+ T cells are composed of functionally heterogeneous subpopulations that differ in their ability to differentiate into type 17 cytotoxic effector cells (Tc17) in a context of murine inflammatory disease models, such as inflammatory bowel disease and graft-versus-host disease. The differential ability of Tc17 differentiation is not related to T-cell receptor (TCR) diversity and antigen specificity but is inversely correlated with self-reactivity acquired during development. Mechanistically, this phenomenon is linked to differential levels of intrinsic TCR sensitivity and basal Suppressor of Mothers Against Decapentaplegic 3 (SMAD3) expression, generating a wide spectrum of Tc17 differentiation potential within naive CD8+ T cell populations. These findings suggest that developmental self-reactivity can determine the fate of naive CD8+ T cells to generate functionally distinct effector populations and achieve immense diversity and complexity in antigen-specific T-cell immune responses. The heterogeneity in naive CD8+ T cells is essential for diverse immune responses. Here the authors show that variations in developmental self-reactivity of CD8+ T cells influence their differentiation into Tc 17 cells in inflammatory conditions. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
20. Obesity-related T cell dysfunction impairs immunosurveillance and increases cancer risk.
- Author
-
Piening, Alexander, Ebert, Emily, Gottlieb, Carter, Khojandi, Niloufar, Kuehm, Lindsey M., Hoft, Stella G., Pyles, Kelly D., McCommis, Kyle S., DiPaolo, Richard J., Ferris, Stephen T., Alspach, Elise, and Teague, Ryan M.
- Subjects
OBESITY paradox ,T cells ,DISEASE risk factors ,WEIGHT loss ,OBESITY complications ,CANCER susceptibility ,CELL physiology - Abstract
Obesity is a well-established risk factor for human cancer, yet the underlying mechanisms remain elusive. Immune dysfunction is commonly associated with obesity but whether compromised immune surveillance contributes to cancer susceptibility in individuals with obesity is unclear. Here we use a mouse model of diet-induced obesity to investigate tumor-infiltrating CD8
+ T cell responses in lean, obese, and previously obese hosts that lost weight through either dietary restriction or treatment with semaglutide. While both strategies reduce body mass, only dietary intervention restores T cell function and improves responses to immunotherapy. In mice exposed to a chemical carcinogen, obesity-related immune dysfunction leads to higher incidence of sarcoma development. However, impaired immunoediting in the obese environment enhances tumor immunogenicity, making the malignancies highly sensitive to immunotherapy. These findings offer insight into the complex interplay between obesity, immunity and cancer, and provide explanation for the obesity paradox observed in clinical immunotherapy settings. Obesity represents a risk factor for cancer and compromises immune function, however the mechanisms linking the two together are not fully known. Here authors show in a mouse sarcoma model that obesity increases tumour incidence, impairs intra-tumoral T cell immunity but paradoxically increases sensitivity to immune therapy via impairing immunoediting. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
21. Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade.
- Author
-
Nie, Hao, Saini, Pratima, Miyamoto, Taito, Liao, Liping, Zielinski, Rafal J., Liu, Heng, Zhou, Wei, Wang, Chen, Murphy, Brennah, Towers, Martina, Yang, Tyler, Qi, Yuan, Kannan, Toshitha, Kossenkov, Andrew, Tateno, Hiroaki, Claiborne, Daniel T., Zhang, Nan, Abdel-Mohsen, Mohamed, and Zhang, Rugang
- Subjects
IMMUNE checkpoint proteins ,FUCOSYLATION ,OVARIAN tumors ,HOMOLOGOUS recombination ,OVARIAN epithelial cancer ,T cells - Abstract
Aberrant glycosylation is a crucial strategy employed by cancer cells to evade cellular immunity. However, it's unclear whether homologous recombination (HR) status-dependent glycosylation can be therapeutically explored. Here, we show that the inhibition of branched N-glycans sensitizes HR-proficient, but not HR-deficient, epithelial ovarian cancers (EOCs) to immune checkpoint blockade (ICB). In contrast to fucosylation whose inhibition sensitizes EOCs to anti-PD-L1 immunotherapy regardless of HR-status, we observe an enrichment of branched N-glycans on HR-proficient compared to HR-deficient EOCs. Mechanistically, BRCA1/2 transcriptionally promotes the expression of MGAT5, the enzyme responsible for catalyzing branched N-glycans. The branched N-glycans on HR-proficient tumors augment their resistance to anti-PD-L1 by enhancing its binding with PD-1 on CD8
+ T cells. In orthotopic, syngeneic EOC models in female mice, inhibiting branched N-glycans using 2-Deoxy-D-glucose sensitizes HR-proficient, but not HR-deficient EOCs, to anti-PD-L1. These findings indicate branched N-glycans as promising therapeutic targets whose inhibition sensitizes HR-proficient EOCs to ICB by overcoming immune evasion. Cancer cells can employ aberrant glycosylation patterns to evade the host immune response. Here the authors report that inhibition of branched N-glycans sensitizes homologous recombination (HR)-proficient, but not HR-deficient, epithelial ovarian cancer to immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
22. Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells.
- Author
-
Bangert, Christine, Alkon, Natalia, Chennareddy, Sumanth, Arnoldner, Tamara, Levine, Jasmine P., Pilz, Magdalena, Medjimorec, Marco A., Ruggiero, John, Cohenour, Emry R., Jonak, Constanze, Damsky, William, Griss, Johannes, and Brunner, Patrick M.
- Subjects
SKIN inflammation ,ATOPIC dermatitis ,NECK ,T cells ,DUPILUMAB ,HEAD ,KERATINOCYTE differentiation - Abstract
Dupilumab, an IL4R-blocking antibody, has shown clinical efficacy for atopic dermatitis (AD) treatment. In addition to conjunctivitis/blepharitis, the de novo appearance of head/neck dermatitis is now recognized as a distinct side effect, occurring in up to 10% of patients. Histopathological features distinct from AD suggest a drug effect, but exact underlying mechanisms remain unknown. We profiled punch biopsies from dupilumab-associated head and neck dermatitis (DAHND) by using single-cell RNA sequencing and compared data with untreated AD and healthy control skin. We show that dupilumab treatment was accompanied by normalization of IL-4/IL-13 downstream activity markers such as CCL13, CCL17, CCL18 and CCL26. By contrast, we found strong increases in type 22-associated markers (IL22, AHR) especially in oligoclonally expanded T cells, accompanied by enhanced keratinocyte activation and IL-22 receptor upregulation. Taken together, we demonstrate that dupilumab effectively dampens conventional type 2 inflammation in DAHND lesions, with concomitant hyperactivation of IL22-associated responses. Dupilumab-associated head and neck dermatitis has been described in a subset of patients treated with the IL4R-blocker dupilumab. Here the authors characterise the immune cell composition and single-cell transcriptome in comparison with untreated forms of atopic dermatitis in a small cohort showing increases in IL-22-associated genes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Bioorthogonal photocatalytic proximity labeling in primary living samples.
- Author
-
Liu, Ziqi, Guo, Fuhu, Zhu, Yufan, Qin, Shengnan, Hou, Yuchen, Guo, Haotian, Lin, Feng, Chen, Peng R., and Fan, Xinyuan
- Subjects
MITOCHONDRIAL proteins ,T cells ,LIPID metabolism ,PROTEOMICS ,CELL culture ,DISEASE progression ,PHOTOPLETHYSMOGRAPHY - Abstract
In situ profiling of subcellular proteomics in primary living systems, such as native tissues or clinic samples, is crucial for understanding life processes and diseases, yet challenging due to methodological obstacles. Here we report CAT-S, a bioorthogonal photocatalytic chemistry-enabled proximity labeling method, that expands proximity labeling to a wide range of primary living samples for in situ profiling of mitochondrial proteomes. Powered by our thioQM labeling warhead development and targeted bioorthogonal photocatalytic chemistry, CAT-S enables the labeling of mitochondrial proteins in living cells with high efficiency and specificity. We apply CAT-S to diverse cell cultures, dissociated mouse tissues as well as primary T cells from human blood, portraying the native-state mitochondrial proteomic characteristics, and unveiled hidden mitochondrial proteins (PTPN1, SLC35A4 uORF, and TRABD). Furthermore, CAT-S allows quantification of proteomic perturbations on dysfunctional tissues, exampled by diabetic mouse kidneys, revealing the alterations of lipid metabolism that may drive disease progression. Given the advantages of non-genetic operation, generality, and spatiotemporal resolution, CAT-S may open exciting avenues for subcellular proteomic investigations of primary samples that are otherwise inaccessible. Studying subcellular proteomes in primary living cells is crucial for understanding health and disease. Here, the authors introduce CAT-S, a non-genetic method based on photocatalysis, enabling in situ deciphering of mitochondrial proteomes in primary cells from mouse tissues and human blood. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
24. Autophagy-enhancing ATG16L1 polymorphism is associated with improved clinical outcome and T-cell immunity in chronic HIV-1 infection.
- Author
-
Schreurs, Renée R. C. E., Koulis, Athanasios, Booiman, Thijs, Boeser-Nunnink, Brigitte, Cloherty, Alexandra P. M., Rader, Anusca G., Patel, Kharishma S., Kootstra, Neeltje A., and Ribeiro, Carla M. S.
- Subjects
IMMUNOSENESCENCE ,HIV ,T cells ,ANTIRETROVIRAL agents ,AUTOPHAGY ,IMMUNITY ,GENETIC variation - Abstract
Chronic HIV-1 infection is characterized by T-cell dysregulation that is partly restored by antiretroviral therapy. Autophagy is a critical regulator of T-cell function. Here, we demonstrate a protective role for autophagy in HIV-1 disease pathogenesis. Targeted analysis of genetic variation in core autophagy gene ATG16L1 reveals the previously unidentified rs6861 polymorphism, which correlates functionally with enhanced autophagy and clinically with improved survival of untreated HIV-1-infected individuals. T-cells carrying ATG16L1 rs6861(TT) genotype display improved antiviral immunity, evidenced by increased proliferation, revamped immune responsiveness, and suppressed exhaustion/immunosenescence features. In-depth flow-cytometric and transcriptional profiling reveal T-helper-cell-signatures unique to rs6861(TT) individuals with enriched regulation of pro-inflammatory networks and skewing towards immunoregulatory phenotype. Therapeutic enhancement of autophagy recapitulates the rs6861(TT)-associated T-cell traits in non-carriers. These data underscore the in vivo relevance of autophagy for longer-lasting T-cell-mediated HIV-1 control, with implications towards development of host-directed antivirals targeting autophagy to restore immune function in chronic HIV-1 infection. T cell dysregulation is a hallmark of chronic HIV-1 infection that is partially restored by antiretroviral therapy. Here the authors show that ATG16L1 rs6861 polymorphism is associated clinically with prolonged control of disease pathogenesis, and functionally with enhanced autophagy and T-cell immunity in chronically HIV-1 infected individuals. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in Systemic Lupus Erythematosus.
- Author
-
Doglio, M., Ugolini, A., Bercher-Brayer, C., Camisa, B., Toma, C., Norata, R., Del Rosso, S., Greco, R., Ciceri, F., Sanvito, F., Casucci, M., Manfredi, A. A., and Bonini, C.
- Subjects
SYSTEMIC lupus erythematosus ,B cells ,REGULATORY T cells ,T cells ,CHIMERIC antigen receptors ,T cell receptors ,IMMUNOLOGICAL tolerance ,IMMUNE system ,HOMEOSTASIS - Abstract
Systemic Lupus Erythematosus (SLE) is a progressive disease leading to immune-mediated tissue damage, associated with an alteration of lymphoid organs. Therapeutic strategies involving regulatory T (Treg) lymphocytes, which physiologically quench autoimmunity and support long-term immune tolerance, are considered, as conventional treatment often fails. We describe here a therapeutic strategy based on Tregs overexpressing FoxP3 and harboring anti-CD19 CAR (Fox19CAR-Tregs). Fox19CAR-Tregs efficiently suppress proliferation and activity of B cells in vitro, which are relevant for SLE pathogenesis. In an humanized mouse model of SLE, a single infusion of Fox19CAR-Tregs restricts autoantibody generation, delay lymphopenia (a key feature of SLE) and restore the human immune system composition in lymphoid organs, without detectable toxicity. Although a short survival, SLE target organs appear to be protected. In summary, Fox19CAR-Tregs can break the vicious cycle leading to autoimmunity and persistent tissue damage, representing an efficacious and safe strategy allowing restoration of homeostasis in SLE. Systemic Lupus Erythematosus (SLE) is a chronic and progressive autoimmune disease characterized by abnormally activated B cells causing organ damage. Here authors introduce an adoptive cell therapy involving regulatory T cells overexpressing FoxP3 and harboring an anti-CD19 CAR to inhibit pathological B cells and thus tissue-harming autoimmunity in a humanized mouse model. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
26. Prior infection with unrelated neurotropic virus exacerbates influenza disease and impairs lung T cell responses.
- Author
-
Foo, Isabelle Jia-Hui, Chua, Brendon Y., Clemens, E. Bridie, So Young Chang, Xiaoxiao Jia, McQuilten, Hayley A., Yiing Yap, Ashley Huey, Cabug, Aira F., Ashayeripanah, Mitra, McWilliam, Hamish E. G., Villadangos, Jose A., Evrard, Maximilien, Mackay, Laura K., Wakim, Linda M., Fazakerley, John K., Kedzierska, Katherine, and Kedzierski, Lukasz
- Subjects
T cells ,SEMLIKI Forest virus ,LUNG diseases ,INFLUENZA viruses ,COMMUNICABLE diseases ,LONG-term memory - Abstract
Immunity to infectious diseases is predominantly studied by measuring immune responses towards a single pathogen, although co-infections are common. In-depth mechanisms on how co-infections impact anti-viral immunity are lacking, but are highly relevant to treatment and prevention. We established a mouse model of co-infection with unrelated viruses, influenza A (IAV) and Semliki Forest virus (SFV), causing disease in different organ systems. SFV infection eight days before IAV infection results in prolonged IAV replication, elevated cytokine/chemokine levels and exacerbated lung pathology. This is associated with impaired lung IAV-specific CD8
+ T cell responses, stemming from suboptimal CD8+ T cell activation and proliferation in draining lymph nodes, and dendritic cell paralysis. Prior SFV infection leads to increased blood brain barrier permeability and presence of IAV RNA in brain, associated with increased trafficking of IAV-specific CD8+ T cells and establishment of long-term tissue-resident memory. Relative to lung IAV-specific CD8+ T cells, brain memory IAV-specific CD8+ T cells have increased TCR repertoire diversity within immunodominant Db NP366 + CD8+ and Db PA224 + CD8+ responses, featuring suboptimal TCR clonotypes. Overall, our study demonstrates that infection with an unrelated neurotropic virus perturbs IAV-specific immune responses and exacerbates IAV disease. Our work provides key insights into therapy and vaccine regimens directed against unrelated pathogens. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
27. Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial.
- Author
-
Ninmer, Emily K., Zhu, Hong, Chianese-Bullock, Kimberly A., von Mehren, Margaret, Haas, Naomi B., Ross, Merrick I., Dengel, Lynn T., and Slingluff Jr, Craig L.
- Subjects
T cells ,SURVIVAL rate ,PEPTIDE vaccines ,TETANUS vaccines ,CANCER vaccines ,MELANOMA ,BRAF genes ,T cell receptors - Abstract
The critical roles of CD4
+ T cells have been understudied for cancer vaccines. Here we report long-term clinical outcomes of a randomized multicenter phase II clinical trial (NCT00118274), where patients with high-risk melanoma received a multipeptide vaccine targeting CD8+ T cells (12MP) and were randomized to receive either of two vaccines for CD4+ (helper) T cells: 6MHP (6 melanoma-specific helper peptides), or tet (a nonspecific helper peptide from tetanus toxoid). Cyclophosphamide (Cy) pre-treatment was also assessed. Primary outcomes for T cell responses to 12MP, 6MHP, and tet were previously reported, suggesting immunogenicity of both vaccines but that CD8 T cell responses to 12MP were lower when tet was replaced with 6MHP. Here, in post-hoc analyses, we report durable prolongation of overall survival by adding 6MHP instead of tet. That benefit was experienced only by male patients. A favorable interaction of 6MHP and Cy is also suggested. Multivariable Cox regression analysis of the intent-to-treat population identify vaccine arm (12MP + 6MHP+Cy) and patient sex (male) as the two significant predictors of enhanced survival. These findings support the value of adding cognate T cell help to cancer vaccines and also suggest a need to assess the impact of patient sex on immune therapy outcomes. Peptide-based cancer vaccines require epitopes for both CD8+ and CD4+ T cells. Here the authors report the long-term outcomes of a randomized phase II trial (NCT00118274) in patients with melanoma designed to evaluate a class I MHC-restricted peptide vaccine plus one of two "helper" peptide preparations to stimulate CD4+ T cells, either non-specific help or melanoma-specific help. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
28. Cancer cell genetics shaping of the tumor microenvironment reveals myeloid cell-centric exploitable vulnerabilities in hepatocellular carcinoma.
- Author
-
Ramirez, Christel F. A., Taranto, Daniel, Ando-Kuri, Masami, de Groot, Marnix H. P., Tsouri, Efi, Huang, Zhijie, de Groot, Daniel, Kluin, Roelof J. C., Kloosterman, Daan J., Verheij, Joanne, Xu, Jing, Vegna, Serena, and Akkari, Leila
- Subjects
CANCER genetics ,TUMOR genetics ,CELL morphology ,VASCULAR endothelial growth factors ,HEPATOCELLULAR carcinoma ,T cells ,RHINORRHEA - Abstract
Myeloid cells are abundant and plastic immune cell subsets in the liver, to which pro-tumorigenic, inflammatory and immunosuppressive roles have been assigned in the course of tumorigenesis. Yet several aspects underlying their dynamic alterations in hepatocellular carcinoma (HCC) progression remain elusive, including the impact of distinct genetic mutations in shaping a cancer-permissive tumor microenvironment (TME). Here, in newly generated, clinically-relevant somatic female HCC mouse models, we identify cancer genetics' specific and stage-dependent alterations of the liver TME associated with distinct histopathological and malignant HCC features. Mitogen-activated protein kinase (MAPK)-activated, Nras
G12D -driven tumors exhibit a mixed phenotype of prominent inflammation and immunosuppression in a T cell-excluded TME. Mechanistically, we report a NrasG12D cancer cell-driven, MEK-ERK1/2-SP1-dependent GM-CSF secretion enabling the accumulation of immunosuppressive and proinflammatory monocyte-derived Ly6Clow cells. GM-CSF blockade curbs the accumulation of these cells, reduces inflammation, induces cancer cell death and prolongs animal survival. Furthermore, GM-CSF neutralization synergizes with a vascular endothelial growth factor (VEGF) inhibitor to restrain HCC outgrowth. These findings underscore the profound alterations of the myeloid TME consequential to MAPK pathway activation intensity and the potential of GM-CSF inhibition as a myeloid-centric therapy tailored to subsets of HCC patients. Distinct genetic mutations can shape the tumor immune microenvironment. Here the authors generate preclinical mouse models of hepatocellular carcinoma bearing clinically-relevant oncogenic driver combinations, identifying myeloid cell-centric exploitable therapeutic vulnerabilities. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
29. Rab4A-directed endosome traffic shapes pro-inflammatory mitochondrial metabolism in T cells via mitophagy, CD98 expression, and kynurenine-sensitive mTOR activation.
- Author
-
Huang, Nick, Winans, Thomas, Wyman, Brandon, Oaks, Zachary, Faludi, Tamas, Choudhary, Gourav, Lai, Zhi-Wei, Lewis, Joshua, Beckford, Miguel, Duarte, Manuel, Krakko, Daniel, Patel, Akshay, Park, Joy, Caza, Tiffany, Sadeghzadeh, Mahsa, Morel, Laurence, Haas, Mark, Middleton, Frank, Banki, Katalin, and Perl, Andras
- Subjects
T cells ,B cells ,GENE expression ,CELL metabolism ,KREBS cycle ,PLASMA cells ,SYSTEMIC lupus erythematosus ,T cell receptors - Abstract
Activation of the mechanistic target of rapamycin (mTOR) is a key metabolic checkpoint of pro-inflammatory T-cell development that contributes to the pathogenesis of autoimmune diseases, such as systemic lupus erythematosus (SLE), however, the underlying mechanisms remain poorly understood. Here, we identify a functional role for Rab4A-directed endosome traffic in CD98 receptor recycling, mTOR activation, and accumulation of mitochondria that connect metabolic pathways with immune cell lineage development and lupus pathogenesis. Based on integrated analyses of gene expression, receptor traffic, and stable isotope tracing of metabolic pathways, constitutively active Rab4A
Q72L exerts cell type-specific control over metabolic networks, dominantly impacting CD98-dependent kynurenine production, mTOR activation, mitochondrial electron transport and flux through the tricarboxylic acid cycle and thus expands CD4+ and CD3+ CD4− CD8− double-negative T cells over CD8+ T cells, enhancing B cell activation, plasma cell development, antinuclear and antiphospholipid autoantibody production, and glomerulonephritis in lupus-prone mice. Rab4A deletion in T cells and pharmacological mTOR blockade restrain CD98 expression, mitochondrial metabolism and lineage skewing and attenuate glomerulonephritis. This study identifies Rab4A-directed endosome traffic as a multilevel regulator of T cell lineage specification during lupus pathogenesis. Activation of the mechanistic target of rapamycin (mTOR) is important in the metabolic function of proinflammatory T cells in autoimmunity. Here the authors characterise how Rab4A is involved with CD98 and endosome recycling which subsequently affects mTOR activation, autoimmunity and T cell expansion. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
30. Proinflammatory polarization of engineered heat-inducible macrophages reprogram the tumor immune microenvironment during cancer immunotherapy.
- Author
-
Xue, Yanan, Yan, Xiaojie, Li, Da, Dong, Shurong, and Ping, Yuan
- Subjects
TUMOR microenvironment ,MACROPHAGES ,IMMUNOTHERAPY ,CELLULAR therapy ,LABORATORY mice ,T cells - Abstract
The success of macrophage-based adoptive cell therapy is largely constrained by poor polarization from alternatively activated (M2-like) to classically activated (M1-like) phenotype in the immunosuppressive tumor microenvironment (TME). Here, we show that the engineered macrophage (eMac) with a heat-inducible genetic switch can induce both self-polarization of adoptively transferred eMac and re-polarization of tumour-associated macrophages in response to mild temperature elevation in a mouse model. The locoregional production of proinflammatory cytokines by eMac in the TME dose not only induces the strong polarization of macrophages into a classically activated phenotype, but also ensures that the side effects typical for systemically administrate proinflammatory cytokines are avoided. We also present a wearable warming device which is adaptable for human patients and can be remotely controlled by a smartphone. In summary, our work represents a safe and efficient adoptive transfer immunotherapy method with potential for human translation. Alternatively activated macrophages have a pivotal role in resolving inflammation but in the tumour microenvironment they are immunosuppressive. Here author show that adoptively transferred engineered macrophages harbouring a heat-inducible genetic switch can resist the polarizing effect of the tumour microenvironment, and do not only remain pro-inflammatory themselves but also re-polarise the endogenous macrophages upon controlled warming with a purpose-made device. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice.
- Author
-
Long, Jianting, Chen, Xihe, He, Mian, Ou, Shudan, Zhao, Yunhe, Yan, Qingjia, Ma, Minjun, Chen, Jingyu, Qin, Xuping, Zhou, Xiangjun, Chu, Junjun, and Han, Yanyan
- Subjects
HUMAN papillomavirus ,T cells ,HLA histocompatibility antigens ,CELLULAR therapy ,CANCER treatment ,ANTINEOPLASTIC agents - Abstract
T cell receptor (TCR)-engineered T cell therapy is a promising potential treatment for solid tumors, with preliminary efficacy demonstrated in clinical trials. However, obtaining clinically effective TCR molecules remains a major challenge. We have developed a strategy for cloning tumor-specific TCRs from long-term surviving patients who have responded to immunotherapy. Here, we report the identification of a TCR (10F04), which is human leukocyte antigen (HLA)-DRA/DRB1*09:01 restricted and human papillomavirus type 18 (HPV18) E7
84-98 specific, from a multiple antigens stimulating cellular therapy (MASCT) benefited metastatic cervical cancer patient. Upon transduction into human T cells, the 10F04 TCR demonstrated robust antitumor activity in both in vitro and in vivo models. Notably, the TCR effectively redirected both CD4+ and CD8+ T cells to specifically recognize tumor cells and induced multiple cytokine secretion along with durable antitumor activity and outstanding safety profiles. As a result, this TCR is currently being investigated in a phase I clinical trial for treating HPV18-positive cancers. This study provides an approach for developing safe and effective TCR-T therapies, while underscoring the potential of HLA class II-restricted TCR-T therapy as a cancer treatment. The use of TCR engineered T cells holds promise for treatment of tumours, but is limited by awareness of clinically effective TCR molecules. Here the authors identify an MHC II restricted TCR that targets viral E7 of human papillomavirus type 18 and show effectivity in a murine model of solid tumour. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
32. Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors.
- Author
-
López, Lucía, Morosi, Luciano Gastón, La Terza, Federica, Bourdely, Pierre, Rospo, Giuseppe, Amadio, Roberto, Piperno, Giulia Maria, Russo, Valentina, Volponi, Camilla, Vodret, Simone, Joshi, Sonal, Giannese, Francesca, Lazarevic, Dejan, Germano, Giovanni, Stoitzner, Patrizia, Bardelli, Alberto, Dalod, Marc, Pace, Luigia, Caronni, Nicoletta, and Guermonprez, Pierre
- Subjects
LUNGS ,DENDRITIC cells ,T cells ,LUNG tumors ,T-cell exhaustion ,CD8 antigen ,NON-small-cell lung carcinoma - Abstract
Cross-presentation by type 1 DCs (cDC1) is critical to induce and sustain antitumoral CD8 T cell responses to model antigens, in various tumor settings. However, the impact of cross-presenting cDC1 and the potential of DC-based therapies in tumors carrying varied levels of bona-fide neoantigens (neoAgs) remain unclear. Here we develop a hypermutated model of non-small cell lung cancer in female mice, encoding genuine MHC-I neoepitopes to study neoAgs-specific CD8 T cell responses in spontaneous settings and upon Flt3L + αCD40 (DC-therapy). We find that cDC1 are required to generate broad CD8 responses against a range of diverse neoAgs. DC-therapy promotes immunogenicity of weaker neoAgs and strongly inhibits the growth of high tumor-mutational burden (TMB) tumors. In contrast, low TMB tumors respond poorly to DC-therapy, generating mild CD8 T cell responses that are not sufficient to block progression. scRNA transcriptional analysis, immune profiling and functional assays unveil the changes induced by DC-therapy in lung tissues, which comprise accumulation of cDC1 with increased immunostimulatory properties and less exhausted effector CD8 T cells. We conclude that boosting cDC1 activity is critical to broaden the diversity of anti-tumoral CD8 T cell responses and to leverage neoAgs content for therapeutic advantage. Response to immune checkpoint inhibitors (ICIs) in patients with non-small cell lung cancer (NSCLC) remains suboptimal, even for tumors with elevated tumor mutational burden. Here the authors generate a model of NSCLC with enhanced mutational load, showing that, while still resistant to ICIs, hypermutated tumors become sensitive to dendritic cell-targeted therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Centrosome amplification and aneuploidy driven by the HIV-1-induced Vpr•VprBP•Plk4 complex in CD4+ T cells.
- Author
-
Park, Jung-Eun, Kim, Tae-Sung, Zeng, Yan, Mikolaj, Melissa, Il Ahn, Jong, Alam, Muhammad S., Monnie, Christina M., Shi, Victoria, Zhou, Ming, Chun, Tae-Wook, Maldarelli, Frank, Narayan, Kedar, Ahn, Jinwoo, Ashwell, Jonathan D., Strebel, Klaus, and Lee, Kyung S.
- Subjects
ANEUPLOIDY ,T cells ,C-terminal residues ,CELL analysis ,UBIQUITIN ligases ,TERNARY forms ,T cell receptors ,GENE amplification - Abstract
HIV-1 infection elevates the risk of developing various cancers, including T-cell lymphoma. Whether HIV-1-encoded proteins directly contribute to oncogenesis remains unknown. We observe that approximately 1–5% of CD4
+ T cells from the blood of people living with HIV-1 exhibit over-duplicated centrioles, suggesting that centrosome amplification underlies the development of HIV-1-associated cancers by driving aneuploidy. Through affinity purification, biochemical, and cellular analyses, we discover that Vpr, an accessory protein of HIV-1, hijacks the centriole duplication machinery and induces centrosome amplification and aneuploidy. Mechanistically, Vpr forms a cooperative ternary complex with an E3 ligase subunit, VprBP, and polo-like kinase 4 (Plk4). Unexpectedly, however, the complex enhances Plk4's functionality by promoting its relocalization to the procentriole assembly and induces centrosome amplification. Loss of either Vpr's C-terminal 17 residues or VprBP acidic region, the two elements required for binding to Plk4 cryptic polo-box, abrogates Vpr's capacity to induce these events. Furthermore, HIV-1 WT, but not its Vpr mutant, induces multiple centrosomes and aneuploidy in human primary CD4+ T cells. We propose that the Vpr•VprBP•Plk4 complex serves as a molecular link that connects HIV-1 infection to oncogenesis and that inhibiting the Vpr C-terminal motif may reduce the occurrence of HIV-1-associated cancers. People living with HIV-1 are at an increased risk of developing various cancers. Here, the authors suggest that HIV-1-encoded Vpr can promote oncogenesis by forming a ternary complex with VprBP and Plk4 and inducing Plk4-dependent centriole overduplication and aneuploidy. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
34. Inactivation of cytidine triphosphate synthase 1 prevents fatal auto-immunity in mice.
- Author
-
Soudais, Claire, Schaus, Romane, Bachelet, Camille, Minet, Norbert, Mouasni, Sara, Garcin, Cécile, Souza, Caique Lopes, David, Pierre, Cousu, Clara, Asnagli, Hélène, Parker, Andrew, Palmquist-Gomes, Paul, Sepulveda, Fernando E., Storck, Sébastien, Meilhac, Sigolène M., Fischer, Alain, Martin, Emmanuel, and Latour, Sylvain
- Subjects
AUTOIMMUNITY ,RNA metabolism ,IMMUNOLOGIC memory ,TALL-1 (Protein) ,T cells ,INTESTINAL mucosa ,T cell receptors - Abstract
De novo synthesis of the pyrimidine, cytidine triphosphate (CTP), is crucial for DNA/RNA metabolism and depends on the CTP synthetases, CTPS1 and −2. Partial CTPS1 deficiency in humans has previously been shown to lead to immunodeficiency, with impaired expansion of T and B cells. Here, we examine the effects of conditional and inducible inactivation of Ctps1 and/or Ctps2 on mouse embryonic development and immunity. We report that deletion of Ctps1, but not Ctps2, is embryonic-lethal. Tissue and cells with high proliferation and renewal rates, such as intestinal epithelium, erythroid and thymic lineages, activated B and T lymphocytes, and memory T cells strongly rely on CTPS1 for their maintenance and growth. However, both CTPS1 and CTPS2 are required for T cell proliferation following TCR stimulation. Deletion of Ctps1 in T cells or treatment with a CTPS1 inhibitor rescued Foxp3-deficient mice from fatal systemic autoimmunity and reduced the severity of experimental autoimmune encephalomyelitis. These findings support that CTPS1 may represent a target for immune suppression. Cytidine nucleotide triphosphate (CTP) is a key precursor involved in the metabolism of DNA, RNA and phospholipids. In this study, the authors examine the physiological consequences of CTP synthase (Ctps) 1 and 2 deletion in vivo and demonstrate that Ctps1 protects mice from fatal autoimmunity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy.
- Author
-
Lupo, Kyle B., Yao, Xue, Borde, Shambhavi, Wang, Jiao, Torregrosa-Allen, Sandra, Elzey, Bennett D., Utturkar, Sagar, Lanman, Nadia A., McIntosh, MacKenzie, and Matosevic, Sandro
- Subjects
KILLER cells ,GLIOBLASTOMA multiforme ,TUMOR-infiltrating immune cells ,PURINERGIC receptors ,ANTIBODY formation ,T cells - Abstract
Severe heterogeneity within glioblastoma has spurred the notion that disrupting the interplay between multiple elements on immunosuppression is at the core of meaningful anti-tumor responses. T cell immunoreceptor with Ig and ITIM domains (TIGIT) and its glioblastoma-associated antigen, CD155, form a highly immunosuppressive axis in glioblastoma and other solid tumors, yet targeting of TIGIT, a functionally heterogeneous receptor on tumor-infiltrating immune cells, has largely been ineffective as monotherapy, suggesting that disruption of its inhibitory network might be necessary for measurable responses. It is within this context that we show that the usurpation of the TIGIT − CD155 axis via engineered synNotch-mediated activation of induced pluripotent stem cell-derived natural killer (NK) cells promotes transcription factor-mediated activation of a downstream signaling cascade that results in the controlled, localized blockade of CD73 to disrupt purinergic activity otherwise resulting in the production and accumulation of immunosuppressive extracellular adenosine. Such "decoy" receptor engages CD155 binding to TIGIT, but tilts inhibitory TIGIT/CD155 interactions toward activation via downstream synNotch signaling. Usurping activities of TIGIT and CD73 promotes the function of adoptively transferred NK cells into intracranial patient-derived models of glioblastoma and enhances their natural cytolytic functions against this tumor to result in complete tumor eradication. In addition, targeting both receptors, in turn, reprograms the glioblastoma microenvironment via the recruitment of T cells and the downregulation of M2 macrophages. This study demonstrates that TIGIT/CD155 and CD73 are targetable receptor partners in glioblastoma. Our data show that synNotch-engineered pluripotent stem cell-derived NK cells are not only effective mediators of anti-glioblastoma responses within the setting of CD73 and TIGIT/CD155 co-targeting, but represent a powerful allogeneic treatment option for this tumor. Given its immunosuppressive effect in glioblastoma (GBM), targeting the TIGIT-CD155 axis presents an attractive therapeutic strategy. Here, the authors develop an adoptive natural killer (iNK) cells therapy with anti-CD155 synNotch-inducible CD73 antibody production to reverse the effect of TIGIT-CD155 signaling for the treatment of GBM. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Author Correction: Human FCHO1 deficiency reveals role for clathrin-mediated endocytosis in development and function of T cells.
- Author
-
Łyszkiewicz, Marcin, Ziętara, Natalia, Frey, Laura, Pannicke, Ulrich, Stern, Marcel, Liu, Yanshan, Fan, Yanxin, Puchałka, Jacek, Hollizeck, Sebastian, Somekh, Ido, Rohlfs, Meino, Yilmaz, Tuğba, Ünal, Ekrem, Karakukcu, Musa, Patiroğlu, Türkan, Kellerer, Christina, Karasu, Ebru, Sykora, Karl-Walter, Lev, Atar, and Simon, Amos
- Subjects
T cells ,ENDOCYTOSIS ,CELL physiology - Abstract
An amendment to this paper has been published and can be accessed via a link at the top of the paper. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation.
- Author
-
van den Bosch, Aletta M. R., van der Poel, Marlijn, Fransen, Nina L., Vincenten, Maria C. J., Bobeldijk, Anneleen M., Jongejan, Aldo, Engelenburg, Hendrik J., Moerland, Perry D., Smolders, Joost, Huitinga, Inge, and Hamann, Jörg
- Subjects
ROOT-tubercles ,MULTIPLE sclerosis ,MICROGLIA ,COMPLEMENT activation ,B cells ,BRAIN diseases ,PHAGOCYTOSIS ,T cells - Abstract
Microglia nodules (HLA-DR
+ cell clusters) are associated with brain pathology. In this post-mortem study, we investigated whether they represent the first stage of multiple sclerosis (MS) lesion formation. We show that microglia nodules are associated with more severe MS pathology. Compared to microglia nodules in stroke, those in MS show enhanced expression of genes previously found upregulated in MS lesions. Furthermore, genes associated with lipid metabolism, presence of T and B cells, production of immunoglobulins and cytokines, activation of the complement cascade, and metabolic stress are upregulated in microglia nodules in MS. Compared to stroke, they more frequently phagocytose oxidized phospholipids and possess a more tubular mitochondrial network. Strikingly, in MS, some microglia nodules encapsulate partially demyelinated axons. Taken together, we propose that activation of microglia nodules in MS by cytokines and immunoglobulins, together with phagocytosis of oxidized phospholipids, may lead to a microglia phenotype prone to MS lesion formation. Microglia nodules are associated with brain pathology. Here, the authors show demyelination in microglia nodules in multiple sclerosis (MS), likely due to oxidized phospholipid phagocytosis and immune activation, suggesting that nodules could be involved in MS lesion formation. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
38. Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice.
- Author
-
Olsen, Anja W., Rosenkrands, Ida, Jacobsen, Christina S., Cheeseman, Hannah M., Kristiansen, Max P., Dietrich, Jes, Shattock, Robin J., and Follmann, Frank
- Subjects
IMMUNOGLOBULINS ,T cells ,CHLAMYDIA ,MICE ,VACCINES ,VACCINE development ,VACCINE effectiveness - Abstract
The clinical development of an effective Chlamydia vaccine requires in-depth understanding of how well protective pre-clinical immune signatures translate to humans. Here, we report a comparative immunological characterization of CTH522/CAF®01 in female mice and humans. We find a range of immune signatures that translate from mouse to human, including a Th1/Th17 cytokine profile and antibody functionality. We identify vaccine-induced T cell epitopes, conserved among Chlamydia serovars, and previously found in infected individuals. Using the mouse model, we show that the common immune signature protected against ascending infection in mice, and vaccine induced antibodies could delay bacterial ascension to the oviduct, as well as development of pathology, in a T cell depleted mouse model. Finally, we demonstrate long-lasting immunity and protection of mice one year after vaccination. Based on the results obtained in the present study, we propose to further investigate CTH522/CAF®01 in a phase IIb study. Authors present a comparative immunological characterisation of Chlamydia vaccine, CTH522/CAF®01, in mice and humans. Findings suggest the mouse to be a good predictor of human immunity to the Chlamydia vaccine CTH522/CAF®01, and long-lasting protection in the mouse further supports the development of this promising vaccine candidate. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.
- Author
-
Bol, Kalijn F., Schreibelt, Gerty, Bloemendal, Martine, van Willigen, Wouter W., Hins-de Bree, Simone, de Goede, Anna L., de Boer, Annemiek J., Bos, Kevin J. H., Duiveman-de Boer, Tjitske, Olde Nordkamp, Michel A. M., van Oorschot, Tom G. M., Popelier, Carlijn J., Pots, Jeanne M., Scharenborg, Nicole M., van de Rakt, Mandy W. M. M., de Ruiter, Valeska, van Meeteren, Wilmy S., van Rossum, Michelle M., Croockewit, Sandra J., and Koeneman, Bouke J.
- Subjects
CLINICAL trials ,T cells ,BRAF genes ,DENDRITIC cells ,CELLULAR therapy ,TUMOR antigens ,MELANOMA - Abstract
Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs (n = 99) or placebo (n = 49). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (p = 0.31). Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88−1.79; p = 0.29). Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73−2.38; p = 0.44). Grade 3−4 study-related adverse events occurred in 5% and 6% of patients. Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p < 0.001). In conclusion, while adjuvant nDC treatment in stage IIIB/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed. Immunotherapy using dendritic cell (DC)-based vaccination has been exploited in the clinic for cancer treatment. Here the authors report the results of a randomized, placebo-controlled, phase 3 trial of adjuvant blood-derived DC cell-based therapy in patients with stage IIIB and IIIC melanoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Converging and evolving immuno-genomic routes toward immune escape in breast cancer.
- Author
-
Blanco-Heredia, Juan, Souza, Carla Anjos, Trincado, Juan L., Gonzalez-Cao, Maria, Gonçalves-Ribeiro, Samuel, Gil, Sara Ruiz, Pravdyvets, Dmytro, Cedeño, Samandhy, Callari, Maurizio, Marra, Antonio, Gazzo, Andrea M., Weigelt, Britta, Pareja, Fresia, Vougiouklakis, Theodore, Jungbluth, Achim A., Rosell, Rafael, Brander, Christian, Tresserra, Francesc, Reis-Filho, Jorge S., and Tiezzi, Daniel Guimarães
- Subjects
T cells ,BREAST cancer ,TRIPLE-negative breast cancer ,CYTOTOXIC T cells ,CANCER invasiveness ,T cell receptors ,CONVERGENT evolution ,MOLECULAR clock - Abstract
The interactions between tumor and immune cells along the course of breast cancer progression remain largely unknown. Here, we extensively characterize multiple sequential and parallel multiregion tumor and blood specimens of an index patient and a cohort of metastatic triple-negative breast cancers. We demonstrate that a continuous increase in tumor genomic heterogeneity and distinct molecular clocks correlated with resistance to treatment, eventually allowing tumors to escape from immune control. TCR repertoire loses diversity over time, leading to convergent evolution as breast cancer progresses. Although mixed populations of effector memory and cytotoxic single T cells coexist in the peripheral blood, defects in the antigen presentation machinery coupled with subdued T cell recruitment into metastases are observed, indicating a potent immune avoidance microenvironment not compatible with an effective antitumor response in lethal metastatic disease. Our results demonstrate that the immune responses against cancer are not static, but rather follow dynamic processes that match cancer genomic progression, illustrating the complex nature of tumor and immune cell interactions. Immune response during breast cancer progression remains to be explored. Here, the characterisation of sequential and parallel multiregion samples of an index patient and a cohort of metastatic triple-negative breast cancers reveals convergent immune evasion mechanisms and an increase in tumor genomic heterogeneity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Regulatory T cells use heparanase to access IL-2 bound to extracellular matrix in inflamed tissue.
- Author
-
Martinez, Hunter A., Koliesnik, Ievgen, Kaber, Gernot, Reid, Jacqueline K., Nagy, Nadine, Barlow, Graham, Falk, Ben A., Medina, Carlos O., Hargil, Aviv, Zihsler, Svenja, Vlodavsky, Israel, Li, Jin-Ping, Pérez-Cruz, Magdiel, Tang, Sai-Wen, Meyer, Everett H., Wrenshall, Lucile E., Lord, James D., Garcia, K. Christopher, Palmer, Theo D., and Steinman, Lawrence
- Subjects
REGULATORY T cells ,EXTRACELLULAR matrix ,T cells ,HEPARANASE ,HEPARAN sulfate proteoglycans ,HEPARAN sulfate ,T cell receptors - Abstract
Although FOXP3
+ regulatory T cells (Treg) depend on IL-2 produced by other cells for their survival and function, the levels of IL-2 in inflamed tissue are low, making it unclear how Treg access this critical resource. Here, we show that Treg use heparanase (HPSE) to access IL-2 sequestered by heparan sulfate (HS) within the extracellular matrix (ECM) of inflamed central nervous system tissue. HPSE expression distinguishes human and murine Treg from conventional T cells and is regulated by the availability of IL-2. HPSE-/- Treg have impaired stability and function in vivo, including in the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. Conversely, endowing monoclonal antibody-directed chimeric antigen receptor (mAbCAR) Treg with HPSE enhances their ability to access HS-sequestered IL-2 and their ability to suppress neuroinflammation in vivo. Together, these data identify a role for HPSE and the ECM in immune tolerance, providing new avenues for improving Treg-based therapy of autoimmunity. Regulatory T cell (Treg ) maintenance and function require IL-2, yet this cytokine is only present in low levels in vivo. In this study, the authors demonstrate that that Treg use heparanase to access IL-2 bound to heparan sulfate proteoglycans in the extracellular matrix of inflamed brain tissue in mice. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
42. Cell softness renders cytotoxic T lymphocytes and T leukemic cells resistant to perforin-mediated killing.
- Author
-
Zhou, Yabo, Wang, Dianheng, Zhou, Li, Zhou, Nannan, Wang, Zhenfeng, Chen, Jie, Pang, Ruiyang, Fu, Haixia, Huang, Qiusha, Dong, Fang, Cheng, Hui, Zhang, Huafeng, Tang, Ke, Ma, Jingwei, Lv, Jiadi, Cheng, Tao, Fiskesund, Roland, Zhang, Xiaohui, and Huang, Bo
- Subjects
CYTOTOXIC T cells ,T cells ,CANCER cells ,YAP signaling proteins ,PERFORINS - Abstract
Mechanical force contributes to perforin pore formation at immune synapses, thus facilitating the cytotoxic T lymphocytes (CTL)-mediated killing of tumor cells in a unidirectional fashion. How such mechanical cues affect CTL evasion of perforin-mediated autolysis remains unclear. Here we show that activated CTLs use their softness to evade perforin-mediated autolysis, which, however, is shared by T leukemic cells to evade CTL killing. Downregulation of filamin A is identified to induce softness via ZAP70-mediated YAP Y357 phosphorylation and activation. Despite the requirements of YAP in both cell types for softness induction, CTLs are more resistant to YAP inhibitors than malignant T cells, potentially due to the higher expression of the drug-resistant transporter, MDR1, in CTLs. As a result, moderate inhibition of YAP stiffens malignant T cells but spares CTLs, thus allowing CTLs to cytolyze malignant cells without autolysis. Our findings thus hint a mechanical force-based immunotherapeutic strategy against T cell leukemia. Cell softness protects cytotoxic T lymphocytes (CTL) from autolysis by own soluble factors such as perforin secreted for killing target cells. Here the authors show that softness can be induced by YAP activation, and that T leukemic cells are more sensitive to YAP inhibition than CTLs, thereby hinting YAP inhibitors as a potential therapy for T leukemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Cell softness renders cytotoxic T lymphocytes and T leukemic cells resistant to perforin-mediated killing.
- Author
-
Zhou, Yabo, Wang, Dianheng, Zhou, Li, Zhou, Nannan, Wang, Zhenfeng, Chen, Jie, Pang, Ruiyang, Fu, Haixia, Huang, Qiusha, Dong, Fang, Cheng, Hui, Zhang, Huafeng, Tang, Ke, Ma, Jingwei, Lv, Jiadi, Cheng, Tao, Fiskesund, Roland, Zhang, Xiaohui, and Huang, Bo
- Subjects
CYTOTOXIC T cells ,T cells ,CANCER cells ,YAP signaling proteins ,PERFORINS - Abstract
Mechanical force contributes to perforin pore formation at immune synapses, thus facilitating the cytotoxic T lymphocytes (CTL)-mediated killing of tumor cells in a unidirectional fashion. How such mechanical cues affect CTL evasion of perforin-mediated autolysis remains unclear. Here we show that activated CTLs use their softness to evade perforin-mediated autolysis, which, however, is shared by T leukemic cells to evade CTL killing. Downregulation of filamin A is identified to induce softness via ZAP70-mediated YAP Y357 phosphorylation and activation. Despite the requirements of YAP in both cell types for softness induction, CTLs are more resistant to YAP inhibitors than malignant T cells, potentially due to the higher expression of the drug-resistant transporter, MDR1, in CTLs. As a result, moderate inhibition of YAP stiffens malignant T cells but spares CTLs, thus allowing CTLs to cytolyze malignant cells without autolysis. Our findings thus hint a mechanical force-based immunotherapeutic strategy against T cell leukemia. Cell softness protects cytotoxic T lymphocytes (CTL) from autolysis by own soluble factors such as perforin secreted for killing target cells. Here the authors show that softness can be induced by YAP activation, and that T leukemic cells are more sensitive to YAP inhibition than CTLs, thereby hinting YAP inhibitors as a potential therapy for T leukemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. TGF-β blockade drives a transitional effector phenotype in T cells reversing SIV latency and decreasing SIV reservoirs in vivo.
- Author
-
Kim, Jinhee, Bose, Deepanwita, Araínga, Mariluz, Haque, Muhammad R., Fennessey, Christine M., Caddell, Rachel A., Thomas, Yanique, Ferrell, Douglas E., Ali, Syed, Grody, Emanuelle, Goyal, Yogesh, Cicala, Claudia, Arthos, James, Keele, Brandon F., Vaccari, Monica, Lorenzo-Redondo, Ramon, Hope, Thomas J., Villinger, Francois, and Martinelli, Elena
- Subjects
T cells ,KILLER cells ,PHENOTYPES ,CELL physiology ,VIRUS reactivation ,VIRAL load ,T cell receptors - Abstract
HIV-1 persistence during ART is due to the establishment of long-lived viral reservoirs in resting immune cells. Using an NHP model of barcoded SIVmac239 intravenous infection and therapeutic dosing of anti-TGFBR1 inhibitor galunisertib (LY2157299), we confirm the latency reversal properties of in vivo TGF-β blockade, decrease viral reservoirs and stimulate immune responses. Treatment of eight female, SIV-infected macaques on ART with four 2-weeks cycles of galunisertib leads to viral reactivation as indicated by plasma viral load and immunoPET/CT with a
64 Cu-DOTA-F(ab')2 -p7D3-probe. Post-galunisertib, lymph nodes, gut and PBMC exhibit lower cell-associated (CA-)SIV DNA and lower intact pro-virus (PBMC). Galunisertib does not lead to systemic increase in inflammatory cytokines. High-dimensional cytometry, bulk, and single-cell (sc)RNAseq reveal a galunisertib-driven shift toward an effector phenotype in T and NK cells characterized by a progressive downregulation in TCF1. In summary, we demonstrate that galunisertib, a clinical stage TGF-β inhibitor, reverses SIV latency and decreases SIV reservoirs by driving T cells toward an effector phenotype, enhancing immune responses in vivo in absence of toxicity. Treatment with the clinical stage TGF-β inhibitor galunisertib promotes latency reversal of HIV/SIV. Here, using a treatment regimen similar to the one tested in clinical trials, the authors show how galunisertib affects immune cell function, increases SIV reactivation, and reduces the viral reservoir in macaques. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
45. A hepatic network of dendritic cells mediates CD4 T cell help outside lymphoid organs.
- Author
-
English, Kieran, Kwan, Rain, Holz, Lauren E., McGuffog, Claire, Krol, Jelte M. M., Kempe, Daryan, Kaisho, Tsuneyasu, Heath, William R., Lisowski, Leszek, Biro, Maté, McCaughan, Geoffrey W., Bowen, David G., and Bertolino, Patrick
- Subjects
T cells ,DENDRITIC cells ,LIVER cells ,CD4 antigen ,LYMPHOID tissue ,IMMUNOLOGIC memory - Abstract
While CD4
+ T cells are a prerequisite for CD8+ T cell-mediated protection against intracellular hepatotropic pathogens, the mechanisms facilitating the transfer of CD4-help to intrahepatic CD8+ T cells are unknown. Here, we developed an experimental system to investigate cognate CD4+ and CD8+ T cell responses to a model-antigen expressed de novo in hepatocytes and reveal that after initial priming, effector CD4+ and CD8+ T cells migrate into portal tracts and peri-central vein regions of the liver where they cluster with type-1 conventional dendritic cells. These dendritic cells are locally licensed by CD4+ T cells and expand the number of CD8+ T cells in situ, resulting in larger effector and memory CD8+ T cell pools. These findings reveal that CD4+ T cells promote intrahepatic immunity by amplifying the CD8+ T cell response via peripheral licensing of hepatic type-1 conventional dendritic cells and identify intrahepatic perivascular compartments specialized in facilitating effector T cell-dendritic cell interactions. Here, English et al. show that after expanding in lymphoid tissues, CD4+ and CD8+ T cells recognising hepatic antigens migrate into specialised vascular liver areas where CD4+ T cells locally license hepatic dendritic cells and further expand CD8+ T cell numbers. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
46. Tumor reactive γδ T cells contribute to a complete response to PD-1 blockade in a Merkel cell carcinoma patient.
- Author
-
Lien, Scott C., Ly, Dalam, Yang, S. Y. Cindy, Wang, Ben X., Clouthier, Derek L., St. Paul, Michael, Gadalla, Ramy, Noamani, Babak, Garcia-Batres, Carlos R., Boross-Harmer, Sarah, Bedard, Philippe L., Pugh, Trevor J., Spreafico, Anna, Hirano, Naoto, Razak, Albiruni R. A., and Ohashi, Pamela S.
- Subjects
T cells ,MERKEL cell carcinoma ,PROGRAMMED cell death 1 receptors ,T-cell exhaustion ,IMMUNE checkpoint proteins ,MERKEL cells ,PATIENT experience - Abstract
Immunotherapies targeting PD-1/PD-L1 are now widely used in the clinic to treat a variety of malignancies. While most of the research on T cell exhaustion and PD-1 blockade has been focused on conventional αβ T cells, the contribution of innate-like T cells such as γδ T cells to anti-PD-1/PD-L1 mediated therapy is limited. Here we show that tumor reactive γδ T cells respond to PD-1 blockade in a Merkel cell carcinoma (MCC) patient experiencing a complete response to therapy. We find clonally expanded γδ T cells in the blood and tumor after pembrolizumab treatment, and this Vγ2Vδ1 clonotype recognizes Merkel cancer cells in a TCR-dependent manner. Notably, the intra-tumoral γδ T cells in the MCC patient are characterized by higher expression of PD-1 and TIGIT, relative to conventional CD4 and CD8 T cells. Our results demonstrate that innate-like T cells could also contribute to an anti-tumor response after PD-1 blockade. Immune checkpoint blockade cancer therapy has been designed to enable tumor killing by conventional αβ T cells. Here authors show that in a Merkel cell carcinoma patient showing complete response to anti-PD-1 treatment, innate-like γδ T cells that specifically recognize the tumor cells expand, and likely contribute to therapeutic success. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Smith-specific regulatory T cells halt the progression of lupus nephritis.
- Author
-
Eggenhuizen, Peter J., Cheong, Rachel M. Y., Lo, Cecilia, Chang, Janet, Ng, Boaz H., Ting, Yi Tian, Monk, Julie A., Loh, Khai L., Broury, Ashraf, Tay, Elean S. V., Shen, Chanjuan, Zhong, Yong, Lim, Steven, Chung, Jia Xi, Kandane-Rathnayake, Rangi, Koelmeyer, Rachel, Hoi, Alberta, Chaudhry, Ashutosh, Manzanillo, Paolo, and Snelgrove, Sarah L.
- Subjects
REGULATORY T cells ,T cells ,LUPUS nephritis ,SYSTEMIC lupus erythematosus ,T cell receptors ,BINDING site assay ,LEUCOCYTES - Abstract
Antigen-specific regulatory T cells (Tregs) suppress pathogenic autoreactivity and are potential therapeutic candidates for autoimmune diseases such as systemic lupus erythematosus (SLE). Lupus nephritis is associated with autoreactivity to the Smith (Sm) autoantigen and the human leucocyte antigen (HLA)-DR15 haplotype; hence, we investigated the potential of Sm-specific Tregs (Sm-Tregs) to suppress disease. Here we identify a HLA-DR15 restricted immunodominant Sm T cell epitope using biophysical affinity binding assays, then identify high-affinity Sm-specific T cell receptors (TCRs) using high-throughput single-cell sequencing. Using lentiviral vectors, we transduce our lead Sm-specific TCR into Tregs derived from patients with SLE who are anti-Sm and HLA-DR15 positive. Compared with polyclonal mock-transduced Tregs, Sm-Tregs potently suppress Sm-specific pro-inflammatory responses in vitro and suppress disease progression in a humanized mouse model of lupus nephritis. These results show that Sm-Tregs are a promising therapy for SLE. Antigen specific regulatory T cells (Treg) play key roles in the peripheral tolerance to suppress autoreactive immune cells and represent potential avenue for therapeutic intervention. Here the authors identify Smith specific Treg and engineer Treg based cell therapy showing suppression of inflammation in a murine model of lupus nephritis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Redox-responsive polymer micelles co-encapsulating immune checkpoint inhibitors and chemotherapeutic agents for glioblastoma therapy.
- Author
-
Zhang, Zhiqi, Xu, Xiaoxuan, Du, Jiawei, Chen, Xin, Xue, Yonger, Zhang, Jianqiong, Yang, Xue, Chen, Xiaoyuan, Xie, Jinbing, and Ju, Shenghong
- Subjects
IMMUNE checkpoint inhibitors ,PROGRAMMED cell death 1 receptors ,CYTOTOXIC T cells ,GLIOBLASTOMA multiforme ,IMMUNOLOGIC memory ,MICELLES ,T cells ,POLYMERSOMES - Abstract
Immunotherapy with immune checkpoint blockade (ICB) for glioblastoma (GBM) is promising but its clinical efficacy is seriously challenged by the blood-tumor barrier (BTB) and immunosuppressive tumor microenvironment. Here, anti-programmed death-ligand 1 antibodies (aPD-L1) are loaded into a redox-responsive micelle and the ICB efficacy is further amplified by paclitaxel (PTX)-induced immunogenic cell death (ICD) via a co-encapsulation approach for the reinvigoration of local anti-GBM immune responses. Consequently, the micelles cross the BTB and are retained in the reductive tumor microenvironment without altering the bioactivity of aPD-L1. The ICB efficacy is enhanced by the aPD-L1 and PTX combination with suppression of primary and recurrent GBM, accumulation of cytotoxic T lymphocytes, and induction of long-lasting immunological memory in the orthotopic GBM-bearing mice. The co-encapsulation approach facilitating efficient antibody delivery and combining with chemotherapeutic agent-induced ICD demonstrate that the chemo-immunotherapy might reprogram local immunity to empower immunotherapy against GBM. Immune checkpoint blockade-based immunotherapy has shown limited efficacy in patients with glioblastoma (GBM). Here the authors describe the design of redox-responsive micelles for increasing the delivery of paclitaxel and anti-PD-L1 in the brain, showing improved anti-tumor immune response in preclinical GBM models. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome.
- Author
-
Hammond, Terese C., Purbhoo, Marco A., Kadel, Sapana, Ritz, Jerome, Nikiforow, Sarah, Daley, Heather, Shaw, Kit, van Besien, Koen, Gomez-Arteaga, Alexandra, Stevens, Don, Ortuzar, Waldo, Michelet, Xavier, Smith, Rachel, Moskowitz, Darrian, Masakayan, Reed, Yigit, Burcu, Boi, Shannon, Soh, Kah Teong, Chamberland, John, and Song, Xin
- Subjects
ADULT respiratory distress syndrome ,CYTOTOXIC T cells ,KILLER cells ,T cells ,T cell receptors ,CELLULAR therapy ,CLINICAL trials ,EXTRACORPOREAL membrane oxygenation - Abstract
Invariant natural killer T (iNKT) cells, a unique T cell population, lend themselves for use as adoptive therapy due to diverse roles in orchestrating immune responses. Originally developed for use in cancer, agenT-797 is a donor-unrestricted allogeneic ex vivo expanded iNKT cell therapy. We conducted an open-label study in virally induced acute respiratory distress syndrome (ARDS) caused by the severe acute respiratory syndrome-2 virus (trial registration NCT04582201). Here we show that agenT-797 rescues exhausted T cells and rapidly activates both innate and adaptive immunity. In 21 ventilated patients including 5 individuals receiving veno-venous extracorporeal membrane oxygenation (VV-ECMO), there are no dose-limiting toxicities. We observe an anti-inflammatory systemic cytokine response and infused iNKT cells are persistent during follow-up, inducing only transient donor-specific antibodies. Clinical signals of associated survival and prevention of secondary infections are evident. Cellular therapy using off-the-shelf iNKT cells is safe, can be rapidly scaled and is associated with an anti-inflammatory response. The safety and therapeutic potential of iNKT cells across diseases including infections and cancer, warrants randomized-controlled trials. Invariant natural killer T (iNKT) cells recognize abnormal cells, but their T cell receptor is not variable and kill cancerous or infected target cells without MHC I restriction. Here, the authors show that in a clinical trial, donor-unrestricted allogeneic iNKT cells could be safely administered to human COVID-19 patients suffering from acute respiratory distress syndrome and trigger an anti-inflammatory response. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Etrolizumab-s fails to control E-Cadherin-dependent co-stimulation of highly activated cytotoxic T cells.
- Author
-
Wiendl, Maximilian, Dedden, Mark, Liu, Li-Juan, Schweda, Anna, Paap, Eva-Maria, Ullrich, Karen A.-M., Hartmann, Leonie, Wieser, Luisa, Vitali, Francesco, Atreya, Imke, Müller, Tanja M., Günther, Claudia, Atreya, Raja, Neurath, Markus F., and Zundler, Sebastian
- Subjects
CYTOTOXIC T cells ,T cells ,CROHN'S disease ,CLINICAL trials ,INFLAMMATORY bowel diseases ,CADHERINS - Abstract
Despite promising preclinical and earlier clinical data, a recent phase III trial on the anti-β7 integrin antibody etrolizumab in Crohn's disease (CD) did not reach its primary endpoint. The mechanisms leading to this outcome are not well understood. Here we characterize the β7
+ T cell compartment from patients with CD in comparison to cells from individuals without inflammatory bowel disease. By flow cytometric, transcriptomic and functional profiling of circulating T cells, we find that triple-integrin-expressing (α4+ β7+ β1hi ) T cells have the potential to home to the gut despite α4β7 blockade and have a specific cytotoxic signature. A subset of triple-integrin-expressing cells readily acquires αE expression and could be co-stimulated via E-Cadherin-αEβ7 interactions in vitro. Etrolizumab-s fails to block such αEβ7 signalling at high levels of T cell stimulation. Consistently, in CD patients treated with etrolizumab, T cell activation correlates with cytotoxic signatures. Collectively, our findings might add one important piece to the puzzle to explain phase III trial results with etrolizumab, while they also highlight that αEβ7 remains an interesting target for future therapeutic approaches in inflammatory bowel disease. The clinical success of anti- αEβ7 antibody Etrolizumab for Crohn's disease is less than what is expected based on proof-of-concept studies. Here authors show, by characterization of T cells from Etrolizumab-treated patients, in vitro functional assays and reanalysis of public single cell datasets on Etrolizumab-treated patients, that at high level of T cell activation, which characterises T cells in Crohn's disease, E-Cadherin-αEβ7 interactions become resistant to Etrolizumab inhibition. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.